Literature DB >> 26517645

Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics.

Peter P Luk1, Christina I Selinger, Timothy J Eviston, Trina Lum, Bing Yu, Sandra A O'Toole, Jonathan R Clark, Ruta Gupta.   

Abstract

Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland malignancy. We evaluate the clinicopathological characteristics and long-term clinical behaviour of MASCs. A total of 190 primary salivary gland malignancies at a single institution were reviewed along with relevant immunohistochemical and fluorescent in situ hybridisation (FISH) studies to identify MASCs. Nine MASCs were identified predominantly in the parotid with an equal incidence in men and women and mean age of 36 years. The tumour size ranged from 14 to 50 mm (mean 22 mm). MASCs were composed of monotonous cells with vacuolated eosinophilic cytoplasm and a small nucleus with a distinctive nucleolus. All cases showed immunoreactivity with S-100, MUC4, CK7 and mammoglobin, and lacked immunoreactivity with DOG1, p63, CK5/6 and calponin. ETV6 rearrangement was seen in all cases. No mutations were identified using the OncoCarta Panel v1.0 Kit. Follow up was available for 0.4 to 22 years (median 4 years). Intraparotid lymph node involvement and local recurrence were seen in one patient each. There were no distant metastases. MASCs have specific histopathological features and immunohistochemical profile that distinguish them from their mimics. FISH plays a confirmatory role. An indolent long-term clinical course was observed in this cohort despite involvement of intraparotid lymph node and microscopically involved/close margins.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26517645     DOI: 10.1097/PAT.0000000000000322

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

1.  Ultrastructural Characterization of Mammary Analogue Secretory Carcinoma of the Salivary Glands: A Distinct Entity from Acinic Cell Carcinoma?

Authors:  Julie Guilmette; Gunnlaugur P Nielsen; William C Faquin; Martin Selig; Vânia Nosé; Anthony W S Chi; Peter M Sadow
Journal:  Head Neck Pathol       Date:  2017-02-13

Review 2.  Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Authors:  Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck Pathol       Date:  2018-11-22

Review 3.  Mammary Analogue Secretory Carcinoma (MASC) of the salivary gland: A new tumor entity.

Authors:  Ivan Damjanov; Faruk Skenderi; Semir Vranic
Journal:  Bosn J Basic Med Sci       Date:  2016-04-21       Impact factor: 3.363

Review 4.  Secretory carcinoma: the eastern Canadian experience and literature review.

Authors:  David Forner; Martin Bullock; Daniel Manders; Timothy Wallace; Christopher J Chin; Liane B Johnson; Matthew H Rigby; Jonathan R Trites; Mark S Taylor; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-11-16

5.  Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.

Authors:  D Gwyn Bebb; Shantanu Banerji; Normand Blais; Patrice Desmeules; Sharlene Gill; Andrea Grin; Harriet Feilotter; Aaron R Hansen; Martin Hyrcza; Monika Krzyzanowska; Barbara Melosky; Jonathan Noujaim; Bibiana Purgina; Dean Ruether; Christine E Simmons; Denis Soulieres; Emina Emilia Torlakovic; Ming-Sound Tsao
Journal:  Curr Oncol       Date:  2021-01-15       Impact factor: 3.677

6.  Secretory carcinoma of the skin: Case report and review of the literature.

Authors:  Robert F Moore; Jonathan D Cuda
Journal:  JAAD Case Rep       Date:  2017-11-08

7.  Characterization of novel genetic alterations in salivary gland secretory carcinoma.

Authors:  Kiyong Na; Juan C Hernandez-Prera; Jae-Yol Lim; Ha Young Woo; Sun Och Yoon
Journal:  Mod Pathol       Date:  2019-12-10       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.